Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
Portfolio Pulse from Lisa Levin
Five health care stocks with high RSI values, indicating potential overbought conditions, have seen significant price movements. EyePoint Pharmaceuticals (EYPT) surged after Phase 2 trial results, Altimmune (ALT) gained on obesity trial results, Omeros Corporation (OMER) rose despite a wider Q3 loss, Terns Pharmaceuticals (TERN) increased after a narrower quarterly loss, and Ocular Therapeutix (OCUL) advanced on a narrower-than-expected quarterly loss.
December 05, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Altimmune's stock increased by 73% over the past month following positive obesity trial results, with an RSI of 91.16 suggesting overbought status.
The recent gains and high RSI indicate that ALT may experience a correction as the market digests the trial results and the stock's rapid ascent.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 85
NEGATIVE IMPACT
EyePoint Pharmaceuticals' stock soared by 198% over five days after announcing positive Phase 2 trial results, with an RSI of 93.44 indicating an overbought condition.
The significant stock price increase and extremely high RSI suggest that EYPT may be due for a short-term pullback as traders may consider taking profits.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Ocular Therapeutix's stock advanced 51% over five days on a narrower-than-expected loss, with an RSI of 77.61 suggesting overbought status.
OCUL's stock may see a short-term correction as the high RSI level often precedes a downturn after such rapid price increases.
CONFIDENCE 55
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Omeros Corporation's stock rose by 87% over the past month despite a wider Q3 loss, with an RSI of 83.06 pointing to overbought territory.
OMER's stock increase, despite negative earnings news, and a high RSI may lead to a price correction as the market reassesses the company's fundamentals.
CONFIDENCE 65
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Terns Pharmaceuticals' stock gained over 56% in five days after a narrower quarterly loss, with an RSI of 79.12 indicating potential overbought conditions.
TERN's recent stock performance and high RSI may attract profit-taking, leading to a short-term price decline.
CONFIDENCE 60
IMPORTANCE 65
RELEVANCE 75